NanoViricides (NYSE:NNVC) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NanoViricides (NYSE:NNVC) in a report released on Monday morning. The brokerage issued a sell rating on the stock.

NanoViricides Stock Down 2.5 %

NNVC opened at $1.15 on Monday. The firm has a market cap of $13.55 million, a P/E ratio of -1.42 and a beta of 0.67. NanoViricides has a 52 week low of $1.00 and a 52 week high of $2.00. The business’s fifty day simple moving average is $1.22 and its 200 day simple moving average is $1.16.

NanoViricides (NYSE:NNVC) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.

Hedge Funds Weigh In On NanoViricides

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in NanoViricides by 7.1% during the third quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock worth $792,000 after buying an additional 30,194 shares during the period. Renaissance Technologies LLC lifted its position in NanoViricides by 72.2% during the first quarter. Renaissance Technologies LLC now owns 76,800 shares of the company’s stock worth $161,000 after buying an additional 32,200 shares during the period. Millennium Management LLC lifted its position in NanoViricides by 59.1% during the fourth quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock worth $75,000 after buying an additional 25,012 shares during the period. Two Sigma Investments LP purchased a new position in NanoViricides during the third quarter worth about $59,000. Finally, UBS Group AG lifted its position in NanoViricides by 114.5% during the first quarter. UBS Group AG now owns 17,448 shares of the company’s stock worth $37,000 after buying an additional 9,314 shares during the period. 10.30% of the stock is currently owned by hedge funds and other institutional investors.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.